Collectively, treatment significantly reduced inflammation and anaemia, accompanied by increasing the numbers of IgG+ IgD− CD27+ CD19+ memory B cells and decreasing the numbers of plasmablasts in UC patients. The gene discussed is CD19; the disease is anemia.